Pirenperone
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Pirenperone ( , , ; developmental code names R-47456 and R-50656) is a serotonin receptor antagonist closely related to ketanserin and risperidone which is described as an antipsychotic and tranquilizer and was never marketed. It is a relatively selective antagonist of the serotonin 5-HT 2A receptor and has been used in scientific research to study the serotonin system.
Its affinities (K i ) for serotonin and other receptors have been reported to be 0.3 to 1.1 nM for the serotonin 5-HT 2A receptor, 6.5 nM for the serotonin 5-HT 7 receptor, 20 nM for the α 1B -adrenergic receptor, 20 nM for the α 2B -adrenergic receptor, 61 nM for the serotonin 5-HT 2B receptor, 60 to 77 nM for the serotonin 5-HT 2C receptor, 485 to 1,700 nM for the serotonin 5-HT 1A receptor, and >1,000 or 6,600 nM for the serotonin 5-HT 1B receptor, whereas other receptors were not reported.
Impact
The elimination half-life of pirenperone has been said to be 4 to 6 hours. In the 1980s, the drug was found to block the effects of the lysergic acid diethylamide (LSD) in animals, and, along with ketanserin, led to the elucidation of the 5-HT 2A receptor as the biological mediator of the effects of serotonergic psychedelics. Along similar lines, there has been interest in pirenperone for potential use as a trip killer against psychedelics in humans.
Evidence and sources
Pirenperone ( , , ; developmental code names R-47456 and R-50656) is a serotonin receptor antagonist closely related to ketanserin and risperidone which is described as an antipsychotic and tranquilizer and was never marketed. It is a relatively selective antagonist of the serotonin 5-HT 2A receptor and has been used in scientific research to study the serotonin system.
Its affinities (K i ) for serotonin and other receptors have been reported to be 0.3 to 1.1 nM for the serotonin 5-HT 2A receptor, 6.5 nM for the serotonin 5-HT 7 receptor, 20 nM for the α 1B -adrenergic receptor, 20 nM for the α 2B -adrenergic receptor, 61 nM for the serotonin 5-HT 2B receptor, 60 to 77 nM for the serotonin 5-HT 2C receptor, 485 to 1,700 nM for the serotonin 5-HT 1A receptor, and >1,000 or 6,600 nM for the serotonin 5-HT 1B receptor, whereas other receptors were not reported.
The elimination half-life of pirenperone has been said to be 4 to 6 hours. In the 1980s, the drug was found to block the effects of the lysergic acid diethylamide (LSD) in animals, and, along with ketanserin, led to the elucidation of the 5-HT 2A receptor as the biological mediator of the effects of serotonergic psychedelics. Along similar lines, there has been interest in pirenperone for potential use as a trip killer against psychedelics in humans.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365881097 under CC BY-SA 4.0; modifications have been made.